Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer

Artikel i vetenskaplig tidskrift
Författare S. Loeb
Y. Folkvaljon
Jan-Erik Damber
J. Alukal
M. Lambe
P. Stattin
Publicerad i Journal of Clinical Oncology
Volym 35
Nummer/häfte 13
Sidor 1430-1436
ISSN 0732-183X
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper
Sidor 1430-1436
Språk en
Länkar dx.doi.org/10.1200/jco.2016.69.5304
Ämnesord cell-proliferation, cohort profile, united-states, sweden, men, castration, apoptosis, register, antigen, growth, Oncology
Ämneskategorier Cancer och onkologi

Sammanfattning

Purpose The association between exposure to testosterone replacement therapy (TRT) and prostate cancer risk is controversial. The objective was to examine this association through nationwide, population-based registry data. We performed a nested case-control study in the National Prostate Cancer Register of Sweden, which includes all 38,570 prostate cancer cases diagnosed from 2009 to 2012, and 192,838 age-matched men free of prostate cancer. Multivariable conditional logistic regression was used to examine associations between TRT and risk of prostate cancer (overall, favorable, and aggressive). Two hundred eighty-four patients with prostate cancer (1%) and 1,378 control cases (1%) filled prescriptions for TRT. In multivariable analysis, no association was found between TRT and overall prostate cancer risk (odds ratio [OR], 1.03; 95% CI, 0.90 to 1.17). However, patients who received TRT hadmore favorable-risk prostate cancer (OR, 1.35; 95% CI, 1.16 to 1.56) and a lower risk of aggressive prostate cancer (OR, 0.50; 95% CI, 0.37 to 0.67). The increase in favorable-risk prostate cancer was already observed within the first year of TRT (OR, 1.61; 95% CI, 1.10 to 2.34), whereas the lower risk of aggressive disease was observed after > 1 year of TRT (OR, 0.44; 95% CI, 0.32 to 0.61). After adjusting for previous biopsy findings as an indicator of diagnostic activity, TRT remained significantly associated with more favorable-risk prostate cancer and lower risk of aggressive prostate cancer. The early increase in favorable-risk prostate cancer among patients who received TRT suggests a detection bias, whereas the decrease in risk of aggressive prostate cancer is a novel finding that warrants further investigation. (C) 2017 by American Society of Clinical Oncology.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?